<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04298502</url>
  </required_header>
  <id_info>
    <org_study_id>HCMV-NKG2C+ NK cell</org_study_id>
    <nct_id>NCT04298502</nct_id>
  </id_info>
  <brief_title>The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human</brief_title>
  <official_title>The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observation study to investigate the molecular mechanism of NKG2C+NK cell
      expansion after HCMV infection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the changes of molecular and gene expression in NK cells at different time
      points after infection, we want to find out the mechanism by which HCMV promotes the
      expansion of NKG2C + NK cells.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CMV viremia</measure>
    <time_frame>2 moths post-transplantation</time_frame>
    <description>CMV-DNA&gt;1.0x10^3 cpies/mL</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>CMV Viremia</condition>
  <condition>Hematopoietic Stem Cell Transplantation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation AND the
        healthy donors.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation

          2. No severe organ dysfunction or failure

          3. Subjects must be capable of, and willing to provide written informed consent to
             participate in the study. Subjects unable to provide written informed consent by
             themselves may be consented through their legal representative.

        Exclusion Criteria:

          1. Participation in another industry-sponsored clinical study where treatment for CMV is
             already specified by the study protocol.

          2. Patients received other adoptive immunotherapy such as donor lymphocyte infusion
             (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojun Huang, M.D., PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiangyu Zhao, M.D., PhD</last_name>
    <phone>+8610-88325949</phone>
    <email>xyz80421@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Institute of Hematology</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangyu Zhao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Xiaojun Huang,MD</investigator_full_name>
    <investigator_title>Head of Peking University Institute of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

